Clinical Trial Update: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating OR2805, a anti-CD163 monoclonal antibody, alone and with anticancer agents for solid tumors, with unspecified status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Head and Neck Squamous Cell Carcinoma
• Leiomyosarcoma
• Liposarcoma
• Malignant Neoplasm
• Melanoma
• Non-small Cell Lung Cancer
• Solid Tumor
• Tumor Solid

Drugs mentioned

• OR2805

Snippet

Sponsor: OncoResponse, Inc. | Conditions: Cancer, Tumor, Solid | Phase 1, Phase 2 | Status: UNKNOWN